Precipio and H3 Biomedicine Sign Second Development Agreement
Precipio, Inc. (PRPO)
US:NASDAQ Investor Relations:
precipiodx.com/investors.html
Company Research
Source: GlobeNewswire
NEW HAVEN, Conn., June 25, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced the initiation of a second development project with H3 Biomedicine that will include the creation of a targeted gene panel. The panel will include a pre-amplification multiplexed PCR that will amplify targeted regions of the key genes of interest. The panel would be used by H3 Biomedicine for their ongoing clinical development programs. H3 Biomedicine was launched in 2011 with an unprecedented $200 million funding commitment from Eisai, a leading global pharmaceutical company pharmaceuticals company, plus additional funding for clinical programs. As a clinical-stage biopharmaceutical company, H3 uniquely leverages their distinct insights from cancer genomics and real-life patient data to advance their projects to clinical proof of concept and beyond. H3 embraces a novel business model in which it collaborates with Eisai to create a prolific drug discovery engin
Show less
Read more
Impact Snapshot
Event Time:
PRPO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRPO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRPO alerts
High impacting Precipio, Inc. news events
Weekly update
A roundup of the hottest topics
PRPO
News
- Precipio Announces Year end 2023 Shareholder Update CallGlobeNewswire
- Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY [Yahoo! Finance]Yahoo! Finance
- Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoYGlobeNewswire
- Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for CancerGlobeNewswire
PRPO
Sec Filings
- 5/1/24 - Form 8-K
- 4/29/24 - Form ARS
- 4/29/24 - Form DEFA14A
- PRPO's page on the SEC website